NovaBay Pharmaceuticals Launches NovaSight™ Daily Vitamin for Ocular Health on Amazon.com
November 18 2019 - 06:50AM
Business Wire
NovaSight complements Avenova® Direct for
comprehensive internal and external eye health
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
the launch of NovaSight™, a proprietary daily vitamin and mineral
supplement specially formulated to support ocular health, on
Amazon.com. NovaSight is a companion product to Avenova® Direct,
NovaBay’s prescription-strength lid and lash spray available on
Amazon.com without a prescription.
NovaSight was formulated by well-known, board-certified
ophthalmologist Robert Abel, Jr., M.D., to replenish vital eye
nutrients. NovaSight contains 23 active ingredients, more than
twice the number as a leading branded eye vitamin and mineral
supplement, and more than three times as many as other popular eye
brands.
NovaSight also contains a higher level of lutein than several
popular brands. Lutein, a xanthophyll and one of 600 known
naturally occurring carotenoids, is synthesized only by plants.
Like other xanthophylls, lutein is found in high quantities in
green leafy vegetables such as spinach, kale and yellow carrots. It
is known to improve or even prevent age-related macular
degeneration, a leading cause of blindness and vision impairment,
and has also been identified as lowering the risk of cataracts.
“As an ophthalmologist with a background in both traditional
medicine and nutrition, I’m delighted to make NovaSight readily
available on Amazon.com to help consumers focus on ocular health,”
said Dr. Abel. “In addition to its comprehensive formulation,
unlike other leading brands, NovaSight has safe levels of zinc and
no copper. Recent medical reports suggest an association between
copper and an increased risk of memory loss and Alzheimer’s
disease. Furthermore, ingesting more than 30 mgs of zinc can
inhibit the absorption of important minerals such as calcium,
magnesium, iodine, selenium and boron. By partnering with
Amazon.com, we are making a significant vitamin formulation
available to the consumer at a very reasonable price.”
“We are delighted to be partnering with Dr. Abel to
commercialize this high-quality ocular vitamin and supplement
product as a complement to Avenova Direct,” said Justin Hall,
NovaBay CEO. “Avenova is proven to treat the underlying causes of
blepharitis and bacterial dry eye. Using NovaSight in combination
with Avenova supports our goal of providing consumers with the
products they need to keep their eyes healthy, both inside and out.
NovaSight is one of several near-term line extensions and
complementary products we plan to introduce to drive cost-effective
growth and leverage our distribution infrastructure.”
About Dr. Robert Abel, Jr.
Dr. Abel earned his medical degree at Jefferson Medical College
in 1969, completed his ophthalmology residency at Mt. Sinai
Hospital and was a Cornea Fellow at the University of Florida. A
board-certified ophthalmologist, Dr. Abel is on the staff of the
Christiana Care Health System. He is the founding member and
President of Delaware Ophthalmology Consultants. He is a former
Clinical Professor of Ophthalmology at Thomas Jefferson University,
and founded and several local and international eye banks. He
teaches locally and internationally on numerous subjects, including
cornea, cataract and nutrition. He co-founded and instructed the
Cornea Microsurgery Workshops at the American Academy of
Ophthalmology and has been on the Academy's Committee of
International Ophthalmology.
Dr. Abel has done active research on corneal transplants,
corneal pathology, contact lenses and drugs as they relate to the
eye. He holds two patents on artificial corneas and has received
the AAO Honor Award and the Senior Honor Award. Dr. Abel recently
authored “The Eye Care Revolution,” which teaches patients how to
treat and reverse common vision problems. He has written and
published several other books on a variety of topics. Dr. Abel is
currently working in Southern Africa to improve eyecare
availability.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding our business strategies and future
focus, the launch of a new product and the impact it may have on
our future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, potential uses of our product, market acceptance, and any
potential regulatory problems. Other risks relating to NovaBay’s
business, including risks that could cause results to differ
materially from those projected in the forward-looking statements
in this press release, are detailed in NovaBay’s latest Form 10-Q/K
filings with the Securities and Exchange Commission, especially
under the heading “Risk Factors.” The forward-looking statements in
this release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay informed on
NovaBay’s progress Like us on Facebook Follow
us on Twitter Connect with NovaBay on LinkedIn Visit
NovaBay’s Website
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191118005175/en/
NovaBay Contact Justin Hall
President and Chief Executive Officer 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Feb 2024 to Mar 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2023 to Mar 2024